Drug Trial Radar · NCT05518708
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
Last checked: Nov 20, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Sep 27, 2022
Primary completion
Sep 21, 2023
Study completion Sep 21, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B) administration of single rising doses.
Conditions
- Healthy
Interventions
BI 3032950Drug
BI 3032950
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with treatment-emergent adverse eventTime frame: Up to 116 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Science Services - Clinical Research
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.